anonymous
Guest
anonymous
Guest
Since the implementation of SFM and the AbbVie regime, we've experienced significant attrition among our top-performing and highly valued colleagues, both representatives and managers. These individuals are choosing to leave, despite the perceived golden handcuffs, prioritizing their mental health. It's ironic that employees are departing a company that professes to value mental well-being, specifically because of the negative impact on their mental health. However, it appears that executive leadership is unmoved by these losses, seemingly prioritizing short-term stock price gains and profit over the long-term health and well-being of their employees. Despite any internal discussions or feedback, often suppressed due to fear of retaliation, it's clear that meaningful change is unlikely. Therefore, employees face a difficult choice: accept the current situation, remain until their stock options vest, or prioritize their mental health and seek opportunities elsewhere. It's time to acknowledge the reality of the situation and stop expecting improvements.
You're either ALL IN to a company plagued by inaccurate forecasting, unrealistic sales goals (achieved by less than half the sales force), a dysfunctional market access team, and a pattern of making impactful decisions about the field, customers, and ultimately, patients, only to announce them retroactively – or you're out. Be realistic: SFM and its big pharma metrics are here to stay and will likely expand. The inevitable outcome is becoming a faceless, voiceless cog in a large, impersonal machine. Or ride that stock and spend your earnings on a good therapist when this is all over.
You're either ALL IN to a company plagued by inaccurate forecasting, unrealistic sales goals (achieved by less than half the sales force), a dysfunctional market access team, and a pattern of making impactful decisions about the field, customers, and ultimately, patients, only to announce them retroactively – or you're out. Be realistic: SFM and its big pharma metrics are here to stay and will likely expand. The inevitable outcome is becoming a faceless, voiceless cog in a large, impersonal machine. Or ride that stock and spend your earnings on a good therapist when this is all over.